Article Text

Download PDFPDF
Irbesartan reduced progression of nephropathy caused by type 2 diabetes independent of the effect on blood pressure

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


 
 QUESTION: In patients with type 2 diabetes mellitus, diabetic nephropathy, and hypertension, what effect does the angiotensin II receptor antagonist (ARA) irbesartan and the calcium channel blocker amlodipine have on renal disease?

Design

Randomised (allocation concealed*), blinded (clinicians, patients, outcome assessors, and statisticians),* placebo controlled trial with mean follow up of 2.6 years (the Irbesartan Diabetic Nephropathy Trial [IDNT]).

Setting

210 clinical centres worldwide.

Patients

1715 patients between 30 and 70 years of age (mean age 59 y, 66% men) who had type 2 diabetes, hypertension, proteinuria defined as a urinary protein excretion rate ≥ 900 mg/24 hours, and serum creatinine concentrations between 88 and 265 μmol/l in women and between 106 and 265 μmol/l in men. Follow up was 99%.

Intervention

Patients were allocated to irbesartan, titrated to 300 mg/day (n=579); amlodipine, titrated to 10 mg/day (n=567); or placebo (n=569). Treatment targeted a systolic blood pressure ≤ 135 mm Hg and a diastolic blood pressure ≤ 85 mm Hg by using drugs other than angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, and calcium channel blockers, if necessary.

Main outcome measures

The primary outcome was the composite of a doubling of the baseline serum creatinine concentration, onset of end stage renal disease, or all cause mortality. The secondary outcome was the composite of cardiovascular mortality, non-fatal myocardial infarction, heart failure resulting in admission to hospital, neurological deficit caused by a cerebrovascular event, or above ankle lower limb amputation.

Main results

Analysis was by intention …

View Full Text

Footnotes

  • * See glossary.

  • Sources of funding: Bristol-Myers Squibb Institute for Medical Research and Sanofi-Synthelabo.

  • For correspondence: Dr E J Lewis, Rush–Presbyterian–St. Luke's Medical Center, Chicago, Illinois, USA.